Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6226079 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7135457 | 0.99 | TACR1 (0.98) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4940003 | 0.94 | TACR1 (0.89) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4939997 | 0.94 | TACR1 (0.89) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4939993 | 0.94 | TACR1 (0.89) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4941367 | 0.93 | TACR1 (0.88) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4941356 | 0.93 | TACR1 (0.88) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4941357 | 0.93 | TACR1 (0.88) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6230972 | 0.93 | TACR1 (0.86) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6226869 | 0.92 | TACR1 (0.86) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1114817-B1 | Substituted benzylamino piperidine compounds | PFIZER (US) | 2004-01-21 | — | — | EP | claimed |
| US-6329396-B1 | TREATMENT OF GASTROINTESTINAL DISORDERS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS; INFLAMMATORY DISEASE; EMESIS; URINARY INCONTINENCE; PAIN; MIGRAINE; SUNBURN; DISEASES, DISORDERS AND ADVERSE CONDITIONS CAUSED BY HELIOBACTER PYLORI; OR | PFIZER INC. | 2001-12-11 | — | — | US | claimed |
| EP-1114817-A1 | Substituted benzylamino piperidine compounds | PFIZER INC. (US) | 2001-07-11 | — | — | EP | claimed |
| US-20040220274-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1114817-B1 | Substituted benzylamino piperidine compounds | PFIZER (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6506775-B1 | Treatment of a gastrointestinal disorder; a central nervous system (CNS) adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans. | PFIZER INC | 2003-01-14 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6329396-B1 | TREATMENT OF GASTROINTESTINAL DISORDERS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS; INFLAMMATORY DISEASE; EMESIS; URINARY INCONTINENCE; PAIN; MIGRAINE; SUNBURN; DISEASES, DISORDERS AND ADVERSE CONDITIONS CAUSED BY HELIOBACTER PYLORI; OR | PFIZER INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1114817-A1 | Substituted benzylamino piperidine compounds | PFIZER INC. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1095655-A2 | NK-1 receptor antagonists and eletriptan for the treatment of migraine | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR1 1/4885CYP2D6 1499/4885KCNH2 182/4885 |
| US-20040220274-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885CYP2D6 1241/4885KCNH2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.